在患有法布里病的患者中SGLT2抑制剂的影响
Malte Lenders1, Sima Canaan-Kühl2, Christine Kurschat3
1Department of Internal Medicine D, and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, Muenster, D-48149, Germany.
概括
依赖的葡萄糖转运体2抑制剂 (SGLT2i) 对法布里病 (FD) 患者是安全的. 减少左心室喷射分数的男性可能受益于SGLT2i,表现为心脏功能改善和功能衰退减缓.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 法布里病 (FD) 是一种多系统性遗传疾病,影响心脏和功能.
- 标准的FD治疗通常需要额外的心脏和脏保护药物.
- 在FD患者中,依赖的葡萄糖转运体2抑制剂 (SGLT2i) 的疗效数据有限.
研究的目的:
- 评估SGLT2抑制剂在患有法布里病的患者中的安全性和有效性.
- 评估SGLT2i对现有治疗中的FD患者心脏和功能的影响.
- 确定SGLT2i在FD患者特定亚组中的潜在益处.
主要方法:
- 多中心回顾性研究,涉及48名法布里病患者接受FD特异性治疗.
- 在三个时间点分析患者数据:SGLT2i前,SGLT2i启动和观察结束 (12个月).
- 评估心脏参数 (例如,左心室喷射率 - LVEF) 和功能 (eGFR).
主要成果:
- SGLT2i治疗是安全的,没有报告的不良事件或与Fabry相关的临床事件.
- 与女性相比,男性表现出较低的基线LVEF.
- 在SGLT2i启动后,男性的估计膜过率 (eGFR) 的下降速度较慢.
- 观察到LVEF的显著改善,特别是在男性的LVEF已经减少 (<50%).
结论:
- SGLT2 抑制剂是法布里病患者的安全补充疗法.
- 通过SGLT2i治疗,对心脏功能产生了潜在的益处,特别是在LVEF降低的男性中.
- 需要进一步的研究来证实这些发现,并优化SGLT2i在法布里病管理中的使用.
相关概念视频
Glucose Transporters
27.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.9K
Dipeptidyl Peptidase 4 Inhibitors
836
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
836
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
722
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
722
Ultrasound II: Endoscopic Ultrasound and FibroScan
954
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
954
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
307
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
307
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
52
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
52


